Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Novel protein kinase inhibitors presented by Priaxon

April 30, 2010

AdventRx to resubmit ANX-530 NDA in fourth quarter of 2010

April 29, 2010

Phase II brostallicin/cisplatin trial in triple-negative breast cancer planned

April 29, 2010

Enrollment complete in OSI's phase III trial of erlotinib in NSCLC

April 29, 2010

In vivo safety and antitumor activity of ABI-013 disclosed

April 29, 2010

Pfizer details discovery and activity of dual PI3K/mTOR inhibitor PF-04691502

April 29, 2010

U.S. scientists claim new fused diimidazodiazepine agents

April 29, 2010

Concert Pharmaceuticals claims new inhibitors of VEGFR-1, -2 and -3

April 29, 2010

TRACON starts phase I/II TRC-105 trial in prostate cancer

April 28, 2010

FDA clears NexMed's phase II PrevOnco trial in advanced unresectable hepatocellular cancer

April 28, 2010

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...